DB04851InvestigationalSmall molecule
The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
- Mechanism
- Curator reviewed
Vertex’s research shows that biricodar dicitrate can enhance the accumulation of chemotherapy agents in tumor cells by blocking the drug pumps P-gp and MRP, and that it is capable of restoring the sensitivity of tumors to treatment with chemotherapeutic agents.
- Primary indication
- Administered intravenously, biricodar dicitrate is to be used in combination with cancer chemotherapy agents.Curator reviewed
- Formula / weight
- C34H41N3O7 · 603.716 g/mol (avg)
- Code names
- VX-710
Resolves to
Clinical / RWD
Structure
InChIKey
CGVWPQOFHSAKRR-NDEPHWFRSA-NSMILESCOC1=CC(=CC(OC)=C1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)OC(CCCC1=CN=CC=C1)CCCC1=CN=CC=C1Transporters
What you can answer from here — as of September 11, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
2TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Biricodar, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account